Transfusion最新文献

{"title":"Double trouble: A baby with concurrent hemolytic disease of the fetus and newborn and neonatal alloimmune thrombocytopenia.","authors":"Regina M DelBaugh, Bryceton Thomas, Brenda J Gower, Brittany Condict, Ashik Luitel, Kelly N Davis, Zbigniew M Szczepiorkowski, Richard M Kaufman, Nancy M Dunbar","doi":"10.1111/trf.18120","DOIUrl":"10.1111/trf.18120","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"252-254"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dissociation of IgM antibodies from red blood cells using ethylenediamine tetraacetate/glycine acid or chloroquine diphosphate.","authors":"Yuko Abe, Hideaki Matsuura, Ayuna Yamada, Rie Nakagawa, Hayato Kojima, Yuya Ishihara, Hiroki Doi, Sumie Fujii, Yasuo Miura","doi":"10.1111/trf.18128","DOIUrl":"10.1111/trf.18128","url":null,"abstract":"<p><strong>Background: </strong>Ethylenediamine tetraacetate/glycine acid (EGA) and chloroquine diphosphate (CDP) are used in transfusion testing to dissociate IgG antibodies from red blood cells (RBCs). However, the ability of these reagents to dissociate IgM antibodies sensitized to RBCs has not been comprehensively elucidated. We investigated whether EGA and CDP could dissociate cold-reactive antibodies from RBCs and their effect on RBCs after dissociation treatment.</p><p><strong>Study design and methods: </strong>Cold-reactive antibody-sensitized RBC samples were prepared by mixing group A RBCs and group B plasma and treated with EGA, CDP, and dithiothreitol (DTT). Before and after the dissociation treatment, changes in the agglutination of these RBCs were assessed using the test tube method. Flow cytometric analysis was used to confirm the nature of antibodies bound to RBCs. Additionally, RBC morphology was evaluated using scanning electron microscopy. This study utilized off-label use of EGA and CDP.</p><p><strong>Results: </strong>Flow cytometric analysis showed that antibodies sensitized to RBCs were mainly IgM antibodies. After antibody dissociation, agglutination disappeared in the EGA-treated samples to the same degree as in the DTT-treated samples. However, IgM antibodies remained in the CDP-treated samples. Regarding RBC morphology, RBC surface appeared coarser in both EGA- and CDP-treated samples, and RBC area was significantly smaller in the CDP-treated samples than in the EGA-treated samples.</p><p><strong>Discussion: </strong>EGA could dissociate cold-reactive antibodies, whereas CDP had a higher residual antibody content. This difference in dissociation ability appears to correlate with the antibody pH of the dissociation reagent. EGA treatment may be useful in cases of sensitization by high-titer cold-reactive antibodies.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"354-362"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron deficiency and infection risk in Danish blood donors.","authors":"Nanna Brøns, Kathrine Agergård Kaspersen, Jakob Thaning Bay, Joseph Dowsett, Christian Erikstrup, Henrik Hjalgrim, Bitten Aagaard, Christina Mikkelsen, Susan Mikkelsen, Ole Birger Pedersen, Klaus Rostgaard, Michael Schwinn, Erik Sørensen, Andreas Stribolt Rigas, Andreas Glenthøj, Sisse Rye Ostrowski","doi":"10.1111/trf.18105","DOIUrl":"10.1111/trf.18105","url":null,"abstract":"<p><strong>Background: </strong>We aimed to investigate if iron deficiency was associated with infection susceptibility in a large cohort of healthy individuals.</p><p><strong>Study design and methods: </strong>The Danish Blood Donor Study is a national ongoing prospective study of blood donors. We included 94,628 donors with 338,290 ferritin measurements from March 2010 to October 2022. We performed sex-stratified multivariable Cox regression to estimate the risk of infection for iron-deficient donors compared with iron-replete donors. Infection was defined as either a filled prescription of antibiotics registered in the Danish National Prescription Registry (NPR), or a hospital contact with infection registered in the Danish National Patient Registry (DNPR).</p><p><strong>Results: </strong>Iron deficiency was associated with an overall increased risk of infection (defined as prescriptions of antibiotics) for women (hazard ratio [HR] 1.08, 95% confidence interval [CI] 1.02-1.15). Subgroup analyses showed an increased risk of respiratory tract infections (HR 1.16, 95% CI 1.05-1.28) and urinary tract infections (HR 1.16, 95% CI 1.04-1.29). Iron deficiency was not associated with overall risk of infection for men (HR 1.02, 95% CI 0.82-1.28). For both men and women, no association was found between iron deficiency and hospital contacts for infections.</p><p><strong>Conclusion: </strong>Iron deficiency was associated with an increased risk of infection in female blood donors. However, effect sizes were small, and there was no association between iron deficiency and hospital contacts for infection. Consequently, risk of infection should not be considered an apprehension regarding blood donation. These findings support the role of iron in immune function and monitorization of iron stores in female blood donors.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"286-296"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing the antibody response to amustaline/glutathione pathogen-reduced red blood cells.","authors":"Christopher Karim, Anil Panigrahi, Ronald G Pearl, Neel R Sodha, Thomas M Beaver, J Peter R Pelletier, Gregory A Nuttall, T Brett Reece, Anna Erickson, Teresa Hedrick, Kathy Liu, Stanley Bentow, Laurence Corash, Nina Mufti, Jeanne Varrone, Richard J Benjamin","doi":"10.1111/trf.18117","DOIUrl":"10.1111/trf.18117","url":null,"abstract":"<p><strong>Background: </strong>The clinical significance of natural and treatment-emergent antibodies specific for amustaline/glutathione pathogen-reduced red blood cells (PRRBCs) is not known.</p><p><strong>Study design and methods: </strong>A Phase 3, randomized clinical trial of PRRBCs (ReCePI) compared PRRBCs with conventional RBCs in cardiac or thoracic-aorta surgery. Subjects transfused during and for 7 days after surgery were screened for PRRBC-specific antibodies at baseline, 28 and 75 days post-surgery. Subjects with treatment-emergent antibodies were assessed for evidence of hemolysis. Cryopreserved subject RBC samples were assayed by flow cytometry for circulating PRRBCs using an acridine-specific (2S197-2M1) monoclonal antibody, and for human IgG-coated RBCs. RBC-surface acridine density was quantitated using a commercial calibrated phycoerythrin (PE)-bead panel.</p><p><strong>Results: </strong>Five of 159 (3.1%) PRRBC and zero of 162 conventional RBC recipients developed treatment-emergent PRRBC-specific IgG, low titer antibodies detected 26-80 days post-surgery after exposure to 1-3 PRRBC units, without clinical evidence of hemolysis. DAT and eluate were weak (w+) positive and PRRBC-specific in one subject. A monocyte monolayer assay (MMA) was non-reactive in the three subjects with an interpretable result. Flow cytometry demonstrated circulating PRRBCs in all five subjects expressing surface acridine concentrations at the limit of detection (approximately 150-301 PE molecules/RBC) compared with freshly transfused PRRBCs (approximately 7500 PE molecules/RBC). In some samples, loss of surface acridine expression could not be distinguished from clearance of the PRRBCs.</p><p><strong>Discussion: </strong>Treatment-emergent PRRBC-specific antibodies with the characteristics of nonclinically significant antibodies were detected in five subjects transfused with PRRBCs. Flow cytometry demonstrated persistent circulating PRRBCs with minimal surface acridine expression. (www.</p><p><strong>Clinicaltrials: </strong>gov Identifier NCT03459287).</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"344-353"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantifying the impact of a novel virus on the economic value of pathogen reduction technology for platelets.","authors":"Adam Irving, Peter Simmonds, William Irving, Stephen Thomas, James Neuberger","doi":"10.1111/trf.18115","DOIUrl":"10.1111/trf.18115","url":null,"abstract":"<p><strong>Background: </strong>Pathogen reduction technology (PRT) is an intervention designed to proactively reduce the amount of known and unknown pathogens in donated blood. As current screening for known pathogens is highly effective, some previous evaluations have found that the value of PRT largely hinges on a previously unknown pathogen, most likely a novel virus, emerging and entering the blood supply. In such situations, the risk of emergence can and should be modeled and presented transparently in the cost-effectiveness results for deliberation by decision-makers.</p><p><strong>Study design and methods: </strong>We built a Markov cohort model assessing the economic value of introducing PRT for platelets in the United Kingdom. Input data were obtained from the existing PRT literature, national sources, or by conservative assumption. The primary objective of the study was to demonstrate methods for modeling and presenting the risk of emergence of a novel virus, using alternative time-to-emergence scenarios in the probabilistic sensitivity analysis.</p><p><strong>Results: </strong>As expected, PRT will be more cost-effective the sooner the novel virus emerges after the introduction of PRT. In the base-case cost scenario, the deterministic ICER was £270 K/QALY gained if the virus emerged immediately and rose to £3.3 M/QALY gained if the virus emerged after 25 years.</p><p><strong>Discussion: </strong>At current prices, PRT is unlikely to be cost-effective when judged against thresholds for medicines and treatments. Given significant additional willingness-to-pay for blood safety, PRT is only likely to be cost-effective if a novel virus that causes chronic infection with significant morbidity and mortality emerges very soon after the introduction of PRT.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"310-317"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-screening donor eligibility to avoid a deferral in the blood donation center: A retrospective cohort study.","authors":"Carley N Gemelli, Surendra Karki, Perfecto Diaz, Andrew Scott, Tanya E Davison","doi":"10.1111/trf.18107","DOIUrl":"10.1111/trf.18107","url":null,"abstract":"<p><strong>Background: </strong>The application of a temporary deferral when attempting to donate has a negative impact on retention. Little has been done to reduce the likelihood of a donor attending to donate, only to be found to be ineligible. The aim of this study was to determine the effectiveness of pre-screening donors when making an appointment, to prevent in-center deferrals.</p><p><strong>Study design and methods: </strong>Donation attempts were collated between July and December 2020. Two segments were identified: (1) those who had a deferral applied and (2) those who successfully donated. Donor and donation characteristics examined included age, sex, prior donation history, deferral history, and appointment booking channel (pre-screened vs. not pre-screened). We also explored the impact of pre-screening on the subsequent donation behavior of those who were deferred.</p><p><strong>Results: </strong>Overall, 3.2% of donation attempts resulted in a deferral being applied. Most donors booked an appointment via a pre-screening channel (69.9%), with the mobile app being the most popular (31.9%). Donors who booked via a pre-screening channel had lower odds of receiving a deferral (aOR: 0.86). Strongest effects were observed for new donors (aOR: 0.79), those aged ≤40 years. (aOR: 0.84) and those deferred in the past (aOR: 0.87). Deferred donors who booked by a pre-screening channel were more likely to return at 6 months (aHR: 1.09) and 12 months (aHR: 1.12) compared to those who did not book through a pre-screening channel.</p><p><strong>Discussion: </strong>Pre-screening donors is a simple and effective approach to reduce the number of donors deferred when presenting to donate in the donation center, with a longer-term impact on donor retention.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"277-285"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic models for prediction of perioperative allogeneic red blood cell transfusion in adult cardiac surgery: A systematic review and meta-analysis.","authors":"Raf Van den Eynde, Annemarie Vrancken, Ruben Foubert, Krizia Tuand, Thomas Vandendriessche, An Schrijvers, Peter Verbrugghe, Timothy Devos, Ben Van Calster, Steffen Rex","doi":"10.1111/trf.18108","DOIUrl":"10.1111/trf.18108","url":null,"abstract":"<p><strong>Objectives: </strong>Identifying cardiac surgical patients at risk of requiring red blood cell (RBC) transfusion is crucial for optimizing their outcome. We critically appraised prognostic models preoperatively predicting perioperative exposure to RBC transfusion in adult cardiac surgery and summarized model performance.</p><p><strong>Methods: </strong>Design: Systematic review and meta-analysis.</p><p><strong>Study eligibility criteria: </strong>Studies developing and/or externally validating models preoperatively predicting perioperative RBC transfusion in adult cardiac surgery. Information sources MEDLINE, CENTRAL & CDSR, Embase, Transfusion Evidence Library, Web of Science, Scopus, ClinicalTrials.gov, and WHO ICTRP. Risk of bias and applicability: Quality of reporting was assessed with the Transparent Reporting of studies on prediction models for Individual Prognosis or Diagnosis adherence form, and risk of bias and applicability with the Prediction model Risk of Bias ASsessment Tool.</p><p><strong>Synthesis methods: </strong>Random-effects meta-analyses of concordance-statistics and total observed:expected ratios for models externally validated ≥5 times.</p><p><strong>Results: </strong>Nine model development, and 27 external validation studies were included. The average TRIPOD adherence score was 66.4% (range 44.1%-85.2%). All studies but 1 were rated high risk of bias. For TRUST and TRACK, the only models externally validated ≥5 times, summary c-statistics were 0.74 (95% CI: 0.65-0.84; 6 contributing studies) and 0.72 (95% CI: 0.68-0.75; 5 contributing studies) respectively, and summary total observed:expected ratios were 0.86 (95% CI: 0.71-1.05; 5 contributing studies) and 0.94 (95% CI: 0.74-1.19; 5 contributing studies), respectively. Considerable heterogeneity was observed in all meta-analyses.</p><p><strong>Discussion: </strong>Future high quality external validation and model updating studies which strictly adhere to reporting guidelines, are warranted.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"397-409"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A spleen is required for antibody mediated immune enhancement but not for RBC clearance or antigen-modulation in mice.","authors":"Ariel M Hay, Arijita Jash","doi":"10.1111/trf.18148","DOIUrl":"https://doi.org/10.1111/trf.18148","url":null,"abstract":"<p><strong>Background: </strong>IgG against alloantigens on transfused RBC can lead to antibody-mediated immune enhancement (AMIE). AMIE has properties not found in other forms of alloimmunization, including rapid clearance of RBCs, a requirement for Fc-gamma receptors on dendritic cells, and no dependence on IFNAR. A spleen is required for alloimmunization to transfused RBCs under normal conditions but its role in AMIE has not been assessed.</p><p><strong>Study design and methods: </strong>Mice with surgical splenectomy or sham surgery were infused with monoclonal IgG against model antigens (HOD or KEL) followed by a transfusion of respective transgenic RBCs. Antibody binding to transfused RBCs, antigen-modulation, and RBC clearance were assessed by flow cytometry. IgM and IgG to the HOD and KEL alloantigens were quantified by flow cytometry-based crossmatch.</p><p><strong>Results: </strong>IgG to either HOD or KEL caused brisk clearance of RBCs with almost complete antigen modulation at 24 h and a strong enhancement of both IgM and IgG in sham-operated animals. In splenectomized animals, AMIE was eliminated; antigen-modulation occurred but with decreased kinetics and magnitude; and RBC clearance was the same as in sham animals.</p><p><strong>Conclusions: </strong>The current study extends the role of spleen as a general requirement for all known pathways of RBC alloimmunization studied thus far. However, the dissociation of clearance and antigen-modulation from AMIE shown in the current study raises the possibility that antigen-modulation and AMIE are correlated due to a confounding common cause (i.e., IgG binding RBCs).</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequent apheresis donation is not associated with adverse bone health in donors aged 45 years and over-Results from a cohort study in Australia.","authors":"Surendra Karki, Md Morshadur Rahman, Andrew Hayen, David O Irving","doi":"10.1111/trf.18146","DOIUrl":"https://doi.org/10.1111/trf.18146","url":null,"abstract":"<p><strong>Background: </strong>We investigated whether frequent apheresis donors have altered risk of bone fractures, and prescription of osteoporosis medicine//s due to their repeated exposure to citrate anticoagulant.</p><p><strong>Methods: </strong>We used the Sax Institute's 45 and Up Study data linked with blood donation and other health-related datasets. We used a \"5-year qualification period\" method to identify active donors who donated at least one (any type) donation in the first and fifth year of the \"qualification period.\" We categorized donors into 0, 1-29, and 30+ donation groups based on the number of apheresis donations made during the qualification period. We then compared the risk of bone fractures, and initiation of osteoporosis medicine/s in the years following the \"qualification period\" between the groups, using Cox proportional-hazards models including several potential confounders.</p><p><strong>Results: </strong>A total of 7369 donors met the qualification criteria, of which 2033 (27.6%) made at least one apheresis donation. Of those donating by apheresis, 381 (18.7%) also made platelet as well as plasma donation, and rest donated plasma only. The median follow-up time for overall bone fractures was 5.49 years/per-donor (Q1-Q3, 5.27-5.95). In the fully adjusted models, compared to donors not making any apheresis donation, the hazard ratio for all-cause bone fractures, osteoporotic bone fractures, and initiation of osteoporosis medicine/s in donors donating 30+ apheresis donations was 0.96 (95% CI: 0.58-1.60), 0.73 (95% CI: 0.29-1.82), and 1.09 (95% CI: 0.66-1.81), respectively.</p><p><strong>Conclusions: </strong>We did not observe a statistically significant change in risk of bone fractures, and initiation of osteoporosis medicine/s in frequent apheresis donors predominantly consisting of plasmapheresis donors.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated plasma testosterone concentrations from males on testosterone replacement therapy are mitigated with pathogen reduction technology.","authors":"B Greenwall, K Reeder, W Anani","doi":"10.1111/trf.18149","DOIUrl":"https://doi.org/10.1111/trf.18149","url":null,"abstract":"<p><strong>Background: </strong>Donors on testosterone replacement therapy (TRT) may require frequent whole blood donation due to erythrocytosis, but FDA guidelines prevent the transfusion of plasma-based products from these donors. This study surveyed TRT donor testosterone levels in whole blood components and evaluated a possible mitigation strategy with a pathogen reduction technology using UVA light and compound adsorption device (CAD) steps.</p><p><strong>Study design and methods: </strong>Whole blood from male TRT donors and controls were processed into red blood cells and plasma components. Free and total testosterone were measured in 78 TRT donors and 48 controls by high-performance liquid chromatography-tandem mass spectrometry. Pathogen reduction (INTERCEPT Blood System) on pooled plasma components (n = 10) with supraphysiologic testosterone were sampled: before treatment, after UVA illumination, and after CAD incubation.</p><p><strong>Results: </strong>TRT donors had 3.8 and 3.9 times more free testosterone in plasma and red blood cell supernatant, respectively, and 2.3 times more total testosterone in both components than controls (p < .0001). Two controls and 33 TRT donors had supraphysiologic testosterone. The CAD incubation reduced the mean free and total testosterone by 88% (571.72-73.8 pg/mL) and 84% (1498.61-240.59 ng/mL), respectively (p = .0065), but UVA light had no effect (p > .9999).</p><p><strong>Discussion: </strong>TRT donors had significantly higher testosterone levels than controls. The CAD step in the pathogen reduction process abrogated supraphysiologic testosterone in plasma at or below the reference range. Studies validating testosterone removal from plasma can support the transfusion of pathogen-reduced plasma and platelets from TRT donors.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}